Development of novel vaccine for oral cancer utilizing endogenous adjuvant
| Project/Area Number |
22791813
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
OHTA Rieko 名古屋市立大学, 医学(系)研究科(研究院), 助教 (30452460)
|
|---|
| Project Period (FY) |
2010-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,193,598 (Direct Cost: ¥3,995,076、Indirect Cost: ¥1,198,522)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,163,598 (Direct Cost: ¥895,076、Indirect Cost: ¥268,522)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 口腔癌 / 補体 / ワクチン / アジュバント / MUC1 / 腫瘍免疫 / 抗体 / 細胞障害性T細胞 |
|---|
| Research Abstract |
MUC1 is a transmembrane glycoprotein normally expressed on epithelial cells. On many types of cancer cell, MUC1 is overexpressed and aberrantly glycosylated, making MUC1 a potential target for cancer immunotherapy. C3d, the final degradation product of the third complement component (C3), can function as a natural adjuvant. We investigated whether a MUC1-C3d fusion protein could enhance MUC1 immunogenicity and break tolerance to MUC1 in MUC1 transgenic mice. Immunization with MUC1-C3d elicited an IgG response and a strong T cell response. In comparison, only a very weak response was seen in mice immunized with MUC1. Furthermore, in human, the treatment of MUC1-C3d to PBMCs resulted in the induction of higher percentage of CD8+ T cells. Thus, C3d functions as an effective molecular adjuvant when linked to a cancer associated self antigen, and may help break MUC1 tolerance in cancer patients.
|
Report
(4 results)
Research Products
(17 results)
